For comments, suggestions
Created with Raphaël 2.1.0 29.09.2017 Filing date 29.04.2019 Validation fee payment 30.09.2019 (A1) Patent application published 14.07.2021 AGEPI application filing date 30.09.2021 (T2) Translation of the validated European patent 22.05.2025 29.09.2025 Valid until 30.09.2026 Renewal fee to be paid until 29.09.2037 Patent will expire on

Patent in force


(210)Number of the EPO application17794060
(220)Filing date of the EPO application2017.09.29
(80)EPO patent specification publication (B)EPB nr. 17/2021, 2021.04.28
(110)EPO patent number3518905
(11)Number of the documentMD 3518905 T2
(21)Number of the applicatione 2019 0876
(71)Name(s) of applicant(s), code of the countrySuven Life Sciences Limited, IN;
(72)Name(s) of inventor(s), code of the countryNIROGI Ramakrishna, IN;
MUDIGONDA Koteshwara, IN;
DOGIPARTI Dhanunjay Kumar, IN;
JASTI Venkateswarlu, IN;
(73)Name(s) of owner(s), code of the countrySUVEN Life Sciences Limited, IN;
(54)Title of the inventionPharmaceutical compositions of 5-HT6 antagonist
(13)Kind-of-document code T2
(51)International Patent Classification A61K 9/20 (2006.01.01); A61K 31/496 (2006.01.01)
(19)CountryIN
(41)Date of publication of the application2019.09.30
(49)Date of publication of the translation of the validated European patent specification2021.09.30
(30)Priority201641033741, 2016.10.03, IN
(74)Patent attorney(Procedură) FOCŞA Valentin, bd. Renaşterii Naţionale, No. 6, of. 08, MD-2024, mun. Chişinău, Republica Moldova
(86)International applicationPCT/IB2017/056009, 2017.09.29
(87)International publicationWO 2018/065869, 2018.04.12
Up
/Inventions/details/3518905